modelHydroxyprogesterone
Extends from Pharmacolibrary.Drugs.ATC.G.G03DA03.
Information
| name: | Hydroxyprogesterone | |
| ATC code: | G03DA03 | route: | intramuscular |
| compartments: | 1 | |
| dosage: | 250 | mg |
| volume of distribution: | 20 | L |
| clearance: | 2 | L/h |
| other parameters in model implementation | ||
Hydroxyprogesterone is a synthetic derivative of progesterone, primarily used for the prevention of recurrent preterm birth in pregnant women with a history of preterm delivery. Historically, it has also been used in hormone therapy and certain gynecological disorders. Hydroxyprogesterone caproate is approved for use in some countries, including the US, but its approval status may vary globally.
Pharmacokinetics
Pharmacokinetic estimates for hydroxyprogesterone caproate in healthy non-pregnant and pregnant women after intramuscular injection.
References
Sharma, S, et al., & Venkataramanan, R (2016). Population pharmacokinetics of 17α-hydroxyprogesterone caproate in singleton gestation. British journal of clinical pharmacology 82(4) 1084–1093. DOI:10.1111/bcp.12990 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27133963
Krop, J, & Kramer, WG (2017). Comparative Bioavailability of Hydroxyprogesterone Caproate Administered via Intramuscular Injection or Subcutaneous Autoinjector in Healthy Postmenopausal Women: A Randomized, Parallel Group, Open-label Study. Clinical therapeutics 39(12) 2345–2354. DOI:10.1016/j.clinthera.2017.10.020 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29191450
Zahradnik, HP (1995). [Depot gestagens]. Archives of gynecology and obstetrics 257(1-4) 536–541. DOI:10.1007/BF02264884 PUBMED:https://pubmed.ncbi.nlm.nih.gov/8579439
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)